Catalyst
Slingshot members are tracking this event:
Ziopharm (ZIOP) Announces Interim Phase 1 Results Assessing Ad-RTS-hIL-12 + Veledimex in Patients with Recurrent Brain Cancer at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ZIOP |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 17, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim Results, Phase 1, Ad-rts-hil-12, Veledimex, Recurrent Brain Cancer, Society For Neuro-oncology, Annual Scientific Meeting
